Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 16/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 13/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16684596 | 1.00 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL9601822 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8866479 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL7280510 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL7280516 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8866477 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL7290562 | 0.76 | CHRNB2 (0.41) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16684570 | 0.76 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16693090 | 0.76 | CHRM1 (0.47) | CHRM1CHRM2CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16693112 | 0.75 | CHRM1 (0.44) | CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015066371-A1 | SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |